ZLLY.NEO ELI LILLY (LLY) BMO CDR (CAD HEDGED)
- Market cap
- CAD 12.9B
- P/E
- 0.4x
- P/B
- 0.26x
- ROE
- 69.3%
- Dividend yield
- 0.55%
- Fundamental score
- 3.2/5
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ZLLY.NEO undervalued?
Graham numberThe Graham number of ELI LILLY (LLY) BMO CDR (CAD HEDGED) cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ELI LILLY (LLY) BMO CDR (CAD HEDGED) fundamental analysis
15 of 22 checks passedROE 2/2
High return on equity (69.3%), above 20%.
ROA 1/1
Return on assets (18.9%) is above the industry median (7.4%).
Profit Consistency 1/2
Profitable for 4 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share history is shorter than 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (95.6%) is above the industry median (90.5%).
Revenue Growth 2/2
Revenue grew 31.7% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
High debt to equity (116.7%), above 100%.
Debt Trend 0/1
Debt to equity history is shorter than 5 years.
Debt Coverage 1/1
Operating cash flow covers 20% of total debt.
Interest Coverage 1/1
No interest expense reported.
PE vs Market 1/1
PE (0.4x) is below the market median (20.3x).
PE vs Industry 1/1
PE (0.4x) is below the industry median (25.0x).
PBV 1/1
Price to book (0.3x) is below the industry median (8.1x).
Graham Number 1/1
The price is below the Graham number (PE x PB = 0.1, limit 22.5).
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 2/2
Dividend yield (74.0%) is in the top 25% of dividend payers in the market.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 1/1
Payout ratio is 26.1%, covered by earnings.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
ELI LILLY (LLY) BMO CDR (CAD HEDGED) stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ELI LILLY (LLY) BMO CDR (CAD HEDGED)
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and…
Full company profileELI LILLY (LLY) BMO CDR (CAD HEDGED) financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ELI LILLY (LLY) BMO CDR (CAD HEDGED) annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 28.5B | 34.1B | 45.0B | 65.2B | 89.6B |
| Gross Profit | 21.9B | 27.0B | 36.6B | 54.1B | 75.2B |
| Operating Income | 8.28B | 10.3B | 17.0B | 29.7B | 47.1B |
| EBITDA | 8.66B | 11.9B | 18.8B | 31.7B | 49.2B |
| Net Income | 6.24B | 5.24B | 10.6B | 20.6B | 27.9B |
| EPS | 6.57 | 5.83 | 12 | 23 | 31 |
| Balance Sheet | |||||
| Total Assets | 49.5B | 64.0B | 78.7B | 112B | 148B |
| Total Liabilities | 38.7B | 53.1B | 64.4B | 85.9B | 108B |
| Shareholders' Equity | 10.6B | 10.8B | 14.3B | 26.5B | 40.3B |
| Cash & Short-term Investments | 2.07B | 2.82B | 3.27B | 7.27B | 4.89B |
| Cash Flow | |||||
| Operating Cash Flow | 7.59B | 4.24B | 8.82B | 16.8B | 36.6B |
| Capital Expenditure | 2.99B | 7.39B | 8.40B | 10.8B | 21.3B |
| Free Cash Flow | 4.60B | -3.15B | 414M | 5.96B | 15.2B |
| Ratios | |||||
| ROE | 58.6% | 48.6% | 74.2% | 77.8% | 69.3% |
| ROA | 12.6% | 8.2% | 13.5% | 18.4% | 18.9% |
| Net Profit Margin | 21.9% | 15.4% | 23.5% | 31.7% | 31.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
ELI LILLY (LLY) BMO CDR (CAD HEDGED) dividends
- Dividend yield
- 0.55%
- Forward dividend
- 0.07 CAD
- Payout ratio
- 26.1%
- Ex-dividend date
- May 15, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 5.38B | 6.02 | 26.1% |
| 2024 | USD 4.68B | 5.21 | 44.2% |
| 2023 | USD 4.07B | 4.52 | 77.7% |
| 2022 | USD 3.54B | 3.72 | 56.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns ELI LILLY (LLY) BMO CDR (CAD HEDGED)
Ownership data of ELI LILLY (LLY) BMO CDR (CAD HEDGED) is not available yet.
ELI LILLY (LLY) BMO CDR (CAD HEDGED) company profile
- Company name
- ELI LILLY (LLY) BMO CDR (CAD HEDGED)
- Ticker
- ZLLY.NEO
- Exchange
- NEO Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 50,000
- Fiscal year end
- December
- Address
- Lilly Corporate Center, Indianapolis, IN, United States, 46285
- Phone
- 317 276 2000
- Website
- lilly.com
About ELI LILLY (LLY) BMO CDR (CAD HEDGED)
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss; Olumiant; Omvoh; and Taltz. Further, it provides Emgality for migraine prevention and episodic cluster headache; and Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; BioArctic AB (publ) for new treatment; QurCan Therapeutics Inc for development of PLNP-enabled genetic medicine therapeutics for the treatment of central nervous system and peripheral nervous system; and Abbisko Therapeutics for discovery and development of medicines across multiple targets. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
ELI LILLY (LLY) BMO CDR (CAD HEDGED) management
10- Mr. David A. RicksChairman, President & CEO · born 1968
- Mr. Lucas E. MontarceExecutive VP & CFO · born 1977
- Dr. Daniel M. Skovronsky M.D., Ph.D.Chief Scientific & Product Officer and President of Lilly Research Laboratories · born 1973
- Ms. Anat Hakim J.D.Executive VP, General Counsel & Secretary · born 1969
- Mr. Jacob S. Van NaardenExecutive VP, President of Lilly Oncology & Head of Corporate Business Development · born 1985
- Mr. Donald A. ZakrowskiSenior VP of Finance & Chief Accounting Officer
- Mr. Diogo RauExecutive VP and Chief Information & Digital Officer · born 1975
- Mr. Michael CzaparSenior Vice President of Investor Relations
- Mr. Eric DozierExecutive VP & Chief People Officer · born 1967
- Mr. Ilya YuffaExecutive VP and President of Lilly USA & Global Customer Capabilities · born 1975